Dandy Ritter
I could not agree more with you on this matter.
I bought in a little under .07 to start
At first I had to pinch myself because after the DD id did on Amarantus I thought although this is high risk/reward wow what a lot of great signs and at the time almost no RED flags.
1. Science/Pipeline
MANF obviously has great potential in many indications that is undeniable whether or not AMBS will be the one to capitalize idk. So literally this company has future on paper in ADHD, Parkinsons (both therapeutic and diagnostic), Diabetes (T&D), Alzheimers (T&D), RP, the list goes on and on. Can't find another biotech out there with a possible role in so many big market indications.
2. Management/Advisors/Directors
I ask myself why in the world would a guy with as much money and clout as Joseph Rubenfeld attach his name to anything that does not have great potential? The guy has already experienced great success in the bio world and is insanely rich..what does he really have to gain by attaching his name to AMBS...nothing. I truly believe that for him to do this its because he believes there is a high potential for success and it will only add to his clout and ego. Prior to the recent conference I also thought WOW what a CEO, this guy could not be any more transparent to the shareholders. Constant communication, clear milestones with a calming sense of confidence. Never seen a stock under a dime where the CEO was so accessible and communicative to the SH.
However, I do not understand at this point how anyone could have confidence in our CEO with out question. Dandy Ritter makes a great point the shanigan with the data can not be swept under the rug. Gerald pumped this compelling data. Now maybe when he stated he wasn't sure what platform they would release he really believed it would be done, and when he realized it wasn't going to be the 15th he truly he believed the 31st was still achievable, just doesn't make any sense. I want to believe that the share increase is completely for justifiable reasons that are solely on the table to strengthen the company and SH value, but I mean cmon this is a penny stock if the end goal was dilution and lining management pockets would you be shocked? Point is up until the Lympro data my confidence was unwavable now I am sleeping with one eye open. I truly question the outcome of a CLIA partner. I have seen endless PR's until I see a big boy PR (complete data, CLIA partner, Grant money etc) Im a lil skeptical
Excuse grammar long day don't really care
I could not agree more with you on this matter.
I bought in a little under .07 to start
At first I had to pinch myself because after the DD id did on Amarantus I thought although this is high risk/reward wow what a lot of great signs and at the time almost no RED flags.
1. Science/Pipeline
MANF obviously has great potential in many indications that is undeniable whether or not AMBS will be the one to capitalize idk. So literally this company has future on paper in ADHD, Parkinsons (both therapeutic and diagnostic), Diabetes (T&D), Alzheimers (T&D), RP, the list goes on and on. Can't find another biotech out there with a possible role in so many big market indications.
2. Management/Advisors/Directors
I ask myself why in the world would a guy with as much money and clout as Joseph Rubenfeld attach his name to anything that does not have great potential? The guy has already experienced great success in the bio world and is insanely rich..what does he really have to gain by attaching his name to AMBS...nothing. I truly believe that for him to do this its because he believes there is a high potential for success and it will only add to his clout and ego. Prior to the recent conference I also thought WOW what a CEO, this guy could not be any more transparent to the shareholders. Constant communication, clear milestones with a calming sense of confidence. Never seen a stock under a dime where the CEO was so accessible and communicative to the SH.
However, I do not understand at this point how anyone could have confidence in our CEO with out question. Dandy Ritter makes a great point the shanigan with the data can not be swept under the rug. Gerald pumped this compelling data. Now maybe when he stated he wasn't sure what platform they would release he really believed it would be done, and when he realized it wasn't going to be the 15th he truly he believed the 31st was still achievable, just doesn't make any sense. I want to believe that the share increase is completely for justifiable reasons that are solely on the table to strengthen the company and SH value, but I mean cmon this is a penny stock if the end goal was dilution and lining management pockets would you be shocked? Point is up until the Lympro data my confidence was unwavable now I am sleeping with one eye open. I truly question the outcome of a CLIA partner. I have seen endless PR's until I see a big boy PR (complete data, CLIA partner, Grant money etc) Im a lil skeptical
Excuse grammar long day don't really care
